Q32 Bio reports Part B data on bempikibart, plans registration trial in 1H 2027

Q32 Bio Inc. reported financial results for the quarter ended September 30, 2026, alongside an update on its alopecia areata program centered on bempikibart. In September 2026, the company presented new data from Part B of the "SIGNAL-AA" Phase 2a clinical trial in late-breaking sessions at the European Academy of Dermatology and Venereology Congress 2026. Part B is an open-label study of bempikibart, a fully human anti-IL-7Rα antibody meant to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling, in 33 patients with severe or very severe AA, who receive the drug for 36 weeks followed by a 16-week off-drug observation period before some enroll in an open-label extension.¹

At week 36, bempikibart showed a mean percent reduction in Severity of Alopecia Tool score from baseline of 35.3% in the modified intent-to-treat population, with 40.0% of patients reaching a SALT-20 response in that analysis and 30.3% reaching it in the full intent-to-treat group.¹ During the 16-week off-drug follow-up, responses were maintained or deepened, and biomarker and biopsy findings supported the drug's mechanism, with no new safety signals reported.¹ Data from the ongoing open-label extension is expected in the second half of 2027.¹

On regulatory timing, Q32 Bio said it intends to move bempikibart into a registration-directed program for severe or very severe AA patients in the first half of 2027, pending regulatory discussions planned for the fourth quarter of 2026.¹ The company also named José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer in September 2026.¹

On financing, Q32 Bio completed a public stock and pre-funded warrant offering in July 2026, raising roughly $200.0 million in gross proceeds before fees.¹ As of September 30, 2026, the company held $289.6 million in cash and cash equivalents, which it said should fund operations through topline Phase 3 results from the planned registration-directed program.¹